Fosun Pharma's Subsidiary to Invest RMB 414 Million in Xingyao Kunze to Advance Hepatology Pipeline

Zhitong Finance APP reports: Fosun Pharmaceutical (02196) announced that on May 26, 2026, 12 new investors, including the Company's holding subsidiary Fosun Pharmaceutical Industry, together with Hepa Thera and its existing shareholders, jointly signed the *Capital Increase and Share Transfer Agreement*. The agreement stipulates, among other things, that: (1) the 12 new investors intend to contribute capital to participate in Hepa Thera's Series B financing, subscribing for a total of RMB 5.305838 million in newly added registered capital (the "Series B Financing"); and (2) six of these new investors also intend to contribute capital to acquire a total of RMB 3.768613 million in the existing registered capital of the target company held by the transferors (namely, Suzhou Fund and Tianjin Fund) (the "Share Transfer"). Specifically, Fosun Pharmaceutical Industry intends to contribute approximately RMB 218 million to subscribe for RMB 2.936752 million in the newly added registered capital of the target company, and contribute approximately RMB 196.6 million to acquire a total of RMB 3.086511 million in the existing registered capital held by the transferors. On the same day, the new investors, together with Hepa Thera and its existing shareholders, also jointly signed the *Shareholders' Agreement*.

The Target Company is primarily engaged in the research and development of innovative drugs for liver diseases. As of the date of this announcement (i.e., May 26, 2026, the same below), its key investigational pipeline includes the innovative siRNA drug HT-101 injection (hereinafter referred to as "HT-101"), the neutralizing antibody HT-102 injection (hereinafter referred to as "HT-102"), and the combination therapy of HT-101 and HT-102, among others. Among these, HT-101 monotherapy and the combination of HT-101 and HT-102 have been respectively included in the Breakthrough Therapy Designation program by the National Medical Products Administration (NMPA).

This investment aims to expand the Group's pipeline portfolio in the liver disease therapeutic area and enhance its core competitiveness in this field.